235 related articles for article (PubMed ID: 30663278)
21. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
22. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
23. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.
Rossetti B; Baldin G; Sterrantino G; Rusconi S; De Vito A; Giacometti A; Gagliardini R; Colafigli M; Capetti A; d'Ettorre G; Celani L; Lagi F; Ciccullo A; De Luca A; Di Giambenedetto S; Madeddu G
Antiviral Res; 2019 Sep; 169():104552. PubMed ID: 31283942
[TBL] [Abstract][Full Text] [Related]
26. Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
Ciccullo A; Baldin G; Capetti A; Borghi V; Sterrantino G; Latini A; Madeddu G; Celani L; Vignale F; Rossetti B; Dusina A; Cossu MV; Restelli S; Gennari W; Lagi F; Giacomelli A; Colafigli M; Brescini L; Borghetti A; Mussini C; Rusconi S; Di Giambenedetto S
BMJ Open; 2019 Dec; 9(12):e029960. PubMed ID: 31796476
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764
[TBL] [Abstract][Full Text] [Related]
28. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Cid-Silva P; Llibre JM; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Martín-Herranz I; Castro-Iglesias Á; Poveda E
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):442-446. PubMed ID: 28627771
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study.
Lee CY; Lee CH; Tang HJ; Tsai HC; Yang CH; Lin YP; Wang SF; Lu PL
Infect Dis Ther; 2023 Mar; 12(3):843-861. PubMed ID: 36520332
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A
J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
[No Abstract] [Full Text] [Related]
31. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.
Modongo C; Wang Q; Dima M; Matsiri O; Kgwaadira B; Rankgoane-Pono G; Shin SS; Zetola NM
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):111-115. PubMed ID: 31335593
[TBL] [Abstract][Full Text] [Related]
32. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
33. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults.
Mendoza I; Lázaro A; Torralba M
Ann Pharmacother; 2022 Apr; 56(4):412-421. PubMed ID: 34293960
[TBL] [Abstract][Full Text] [Related]
36. Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.
Zheng A; Kumarasamy N; Huang M; Paltiel AD; Mayer KH; Rewari BB; Walensky RP; Freedberg KA
J Int AIDS Soc; 2018 Mar; 21(3):e25085. PubMed ID: 29603882
[TBL] [Abstract][Full Text] [Related]
38. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Patel DA; Snedecor SJ; Tang WY; Sudharshan L; Lim JW; Cuffe R; Pulgar S; Gilchrist KA; Camejo RR; Stephens J; Nichols G
PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312
[TBL] [Abstract][Full Text] [Related]
39. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
Chang HM; Chou CH; Tsai HC
BMC Infect Dis; 2022 Jan; 22(1):2. PubMed ID: 34983388
[TBL] [Abstract][Full Text] [Related]
40. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]